Patient Ambassador

NCT06711380 | Completed

• 2 other identifiers: UPCC 33823854317
• Study Type: interventional
• Target: 23
• Locations: 1 country
• Sites: 1

Brief Summary

The overall objective of this study is to design and evaluate a peer ambassador intervention to improve gynecologic cancer trial enrollment. The primary Aim is to determine the possibility of using peer ambassadors to increase discussion, awareness, and enrollment of patients with advanced or recurrent gynecologic cancer onto clinical trials.

Conditions

Gynecologic Cancer

Keywords

mentor; ambassador; gynecologic cancer

Outcome Measures

Primary Outcomes (3)

• Feasibility of the ambassador program

  Feasibility of the ambassador program will be assessed using the Feasibility of Intervention Measure (FIM). The FIM is a 4-item questionnaire measuring the feasibility of an intervention.

  12 months

• Acceptability of the ambassador program

  Acceptability of this program will be assessed using AIM (Acceptability of Intervention Measure). The AIM is a 4-item questionnaire measuring the acceptability of an intervention.

  12 months

• Intention

  Intention to recommend the ambassador program will be assessed using the Net Promoter Score (NPS) measure. NPS instrument is attached in the appendix and does not require any licensing agreement for use in this research study. Participants will be asked to rate the likelihood of their referral of the program on a scale of zero to ten (zero to six is a "Detractor", while scores of seven to eight are "Passives" and scores of nine and ten are "Promoters").

  12 months

Secondary Outcomes (3)

• Mentee knowledge

  2 months

• Sociodemographic

  2 months

• Clinical trial enrollment

  12 months

Study Arms (1)

Peer Ambassador

OTHER

There is one arm of the trial which includes the Patient Ambassador intervention.

Other: Peer Ambassador

Interventions

Peer Ambassador OTHER

Patient mentor (patient with history of gynecologic cancer who has experience with clinical trials) one on one discussion with patient mentee (patient receiving standard of care treatment for gynecologic cancers).

Peer Ambassador

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Eligible subjects will include those with advanced gynecologic cancer (metastatic or persistent/progressive disease despite primary treatment) or high-risk gynecologic cancer undergoing active systemic therapy not currently enrolled on clinical trials. These patients include those starting a new line of chemotherapy, or who have a diagnosis needing chemotherapy.
• Patients will be identified from the UPHS gynecologic oncology and medical oncology clinics serving gynecologic cancer patients (Penn Medicine Washington Square, PCAM/HUP, Radnor, Chester County, Penn Medicine Cherry Hill). Clinic rosters over 6 months intervals will be screened for eligibility.
• Patients who have been discussed at tumor board conferences and recommended to consider clinical trials will screened for recruitment.

You may not qualify if:

• N/A

Sponsors & Collaborators

• Abramson Cancer Center at Penn Medicine: lead

Study Sites (1)

Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, 19104, United States

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Director, Pennsylvania Hospital Abramson Cancer Center, Director, Gynecologic Oncology Populations Sciences Research Program, Director, REACH - Research Equity Center for Gynecologic Cancers and Health

Study Record Dates

• First Submitted: October 18, 2024
• First Posted: December 2, 2024
• Study Start: February 9, 2024
• Primary Completion: October 31, 2025
• Study Completion: October 31, 2025
• Last Updated: February 24, 2026

Record last verified: 2024-11

Locations

US (1)